Quince Therapeutics appoints June Bray as independent director, expands board to four members

Quince Therapeutics, Inc.

June Bray appointed as Class I director effective April 22, 2026, filling a vacancy on the four-member board.
Bray is deemed independent and will serve on Nominating & Governance, Audit, and Compensation Committees.
Director compensation: $38,000 annual board retainer plus $7,500 (Nominating & Gov), $5,500 (Audit), $4,000 (Comp); no initial option grant.
Bray will enter the company's standard form of indemnification agreement.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.